UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2025

Commission file number: 001-41557

CLEARMINDMEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

CONTENTS

Attachedhereto and incorporated herein is Clearmind Medicine Inc.’s (the “Company”) press release issued on October 31,2025, titled “Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for ItsNon-Hallucinogenic Neuroplastogen MEAI Therapy”.

In addition, as previously announced, on September 17, 2025, the Company entered into a definitivesecurities purchase agreements with investors pursuant to which the Company shall issue and sell, from time to time, convertible promissorynotes (the “Notes”) in the aggregate principal amount of up to $10,000,000. On October 30, 2025 and October 31, 2025, an aggregateof $1,045,062 of outstanding amounts due under the Notes were converted into 885,000 of the Company’s common shares.

This Form 6-K and the firstthree paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into theRegistrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293)and Form S-8 (File No. 333-283695),filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to theextent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements ofthe Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoduly authorized.

Exhibit 99.1

Clearmind Medicine Advances Fight Against Cocaine Addiction with Publicationof U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy

Vancouver, Canada, Oct. 31, 2025 (GLOBE NEWSWIRE) -- ClearmindMedicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech companyfocused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems,today announced the publication of a U.S. patent application expanding coverage of its non-hallucinogenic proprietary compound,5-methoxy-2-aminoindane (MEAI), for the treatment of cocaine addiction.

The application strengthens Clearmind’s growing intellectualproperty portfolio and reinforces MEAI’s potential to address a major unmet medical need. Cocaine use disorder affects millionsworldwide and currently has no FDA-approved pharmacological treatment. The global market for cocaine addiction treatment is estimatedat $1.36 billion in 2025 and is projected to grow to $2.03 billion by 2032, highlighting the urgent demand for new and effective solutions.

MEAI is a novel, non-hallucinogenic neuroplastogen designed to modulateserotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. This approach could offer a safer, scalablealternative to existing behavioral interventions.

“Securing protection for MEAI’s potential use in cocaineaddiction supports our broader strategy to build a robust pipeline of non-hallucinogenic neuroplastogens,” said Adi Zuloff-Shani,Ph.D., CEO of Clearmind Medicine. “We believe this patent filing represents another key step in positioning Clearmind as a leaderin next-generation addiction therapeutics.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech companyfocused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems,including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercializethem as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of nineteenpatent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted andwill remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol“CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information visit: https://www.clearmindmedicine.com orcontact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements”within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,”“intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressionsor variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statementswhen it discusses its growing intellectual property portfolio, MEAI potential to address a major unmet medical need, the growth of themarket for the treatment of cocaine use disorder, the Company’s strategy to build a robust pipeline of non-hallucinogenic neuroplastogensand positioning Clearmind as a leader in next-generation addiction therapeutics. Forward-looking statements are not historical facts,and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’sexpectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicatedby the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performanceor results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks anduncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securitiesand Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report onForm 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak onlyas of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results,subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except tothe extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference shouldbe drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. Referencesand links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by referenceinto this press release. Clearmind is not responsible for the contents of third-party websites.